General Overview of Pipeline
Catalyst Biosciences (CBIO) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates that regulate bleeding and is advancing two candidates into mid-stage clinical trials:
Source: Company's October 2018 investor presentation
The most advanced program, a subcutaneously, SQ, administered, next-generation engineered coagulation Factor VIIa, activated marzeptacog alfa (MarzAA), is enrolling hemophilia patients with an inhibitor in a Phase 2/3 SQ dosing trial. The Phase 2 part of this